Clinical Trial

A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of TAS-205 in patients with Duchenne muscular dystrophy
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-10-13; most recent amendment 2025-09-04.
Status change: Recruiting → Active, Not Recruiting 2024-08-13
Status change: Not Yet Recruiting → Recruiting 2021-02-04
Trial Details
NCT Number NCT04587908
Lead Sponsor Taiho Pharmaceutical Co., Ltd.
Conditions Duchenne Muscular Dystrophy
Enrollment 104 participants
Start Date 2020-11-01
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-09-11